AI Science Tracker
EN

Second Department of Radiology

1 discovery from 2024

Discoveries

A novel radiomics approach for predicting TACE outcomes in hepatocellular carcinoma patients using deep learning for multi-organ segmentation.

Source check: Source checked. Not independent scientific confirmation.

Finding: original PDF confirms pretrained DL segmentation enabled multi-organ radiomics and survival modeling after TACE in 252 patients; retrospective associations and stated need for external/prospective validation retained.

Technology: Pretrained deep-learning segmentation identifies multiple organs on CT for radiomics-based prediction of outcomes after transarterial chemoembolization in hepatocellular carcinoma.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Pretrained deep-learning segmentation identifies multiple organs on CT for radiomics-based prediction of outcomes after transarterial chemoembolization in hepatocellular carcinoma.
Test and result
In 252 patients, the pipeline combined multi-organ segmentation with radiomics and survival modeling to estimate TACE outcomes.
Limitation / still unknown
Retrospective associations require external and prospective validation; no treatment benefit is established.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://europepmc.org/article/MED/38926517 · https://www.nature.com/articles/s41598-024-65630-z.pdf · https://pubmed.ncbi.nlm.nih.gov/38926517/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.